IL17A and psoriasis: Figure 3 showed the forest plots of including studies investigating the differences in the rate of COVID-19 infection, hospitalization and mortality between the patients with psoriasis receiving IL-17 inhibitors (secukinumab, ixekizumab, or brodalumab) and those receiving non-biologics (topical therapies, phototherapy, acitretin, methotrexate, cyclosporine, apremilast and dimetil-fumarate).